NO20050619L - Strukturelle korotenoid analoger for inhibisjon og lindring av sykdom - Google Patents
Strukturelle korotenoid analoger for inhibisjon og lindring av sykdomInfo
- Publication number
- NO20050619L NO20050619L NO20050619A NO20050619A NO20050619L NO 20050619 L NO20050619 L NO 20050619L NO 20050619 A NO20050619 A NO 20050619A NO 20050619 A NO20050619 A NO 20050619A NO 20050619 L NO20050619 L NO 20050619L
- Authority
- NO
- Norway
- Prior art keywords
- analog
- combination
- administered
- relief
- inhibition
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title abstract 6
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 150000003254 radicals Chemical class 0.000 abstract 6
- 235000021466 carotenoid Nutrition 0.000 abstract 3
- 150000001747 carotenoids Chemical class 0.000 abstract 3
- 229910017464 nitrogen compound Inorganic materials 0.000 abstract 3
- 150000002830 nitrogen compounds Chemical class 0.000 abstract 3
- 150000002927 oxygen compounds Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 150000001514 astaxanthins Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/24—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/58—One oxygen atom, e.g. butenolide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39919402P | 2002-07-29 | 2002-07-29 | |
US46797303P | 2003-05-05 | 2003-05-05 | |
US47283103P | 2003-05-22 | 2003-05-22 | |
US47374103P | 2003-05-28 | 2003-05-28 | |
US48530403P | 2003-07-03 | 2003-07-03 | |
PCT/US2003/023706 WO2004011423A2 (en) | 2002-07-29 | 2003-07-29 | Structural carotenoid analogs for the inhibition and amelioration of disease |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20050619L true NO20050619L (no) | 2005-04-27 |
Family
ID=31192475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20050619A NO20050619L (no) | 2002-07-29 | 2005-02-03 | Strukturelle korotenoid analoger for inhibisjon og lindring av sykdom |
Country Status (12)
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070160645A1 (en) * | 2001-10-25 | 2007-07-12 | Jakob Vinten-Johansen | PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs |
WO2003035142A2 (en) | 2001-10-25 | 2003-05-01 | Emory University | Catheter for modified perfusion |
US7759506B2 (en) * | 2002-02-25 | 2010-07-20 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
JP2005518453A (ja) * | 2002-02-25 | 2005-06-23 | ディフュージョン・ファーマシューティカルズ・エルエルシー | 二極性トランスカロテノイド塩およびそれらの使用 |
US20050004235A1 (en) * | 2002-07-29 | 2005-01-06 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease |
US20050059659A1 (en) * | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for controlling C-reactive protein levels |
US7723327B2 (en) * | 2002-07-29 | 2010-05-25 | Cardax Pharmaceuticals, Inc. | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease |
CA2495167C (en) | 2002-07-29 | 2018-08-21 | Hawaii Biotech, Inc. | Structural carotenoid analogs for the inhibition and amelioration of disease |
US20050009788A1 (en) * | 2002-07-29 | 2005-01-13 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling connexin 43 expression |
US20050049248A1 (en) * | 2002-07-29 | 2005-03-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels |
US7345091B2 (en) * | 2002-07-29 | 2008-03-18 | Cardax Pharmaceuticals, Inc. | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
US20050059635A1 (en) * | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels |
US7320997B2 (en) * | 2002-07-29 | 2008-01-22 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease |
US7763649B2 (en) * | 2002-07-29 | 2010-07-27 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for controlling connexin 43 expression |
US7375133B2 (en) * | 2002-07-29 | 2008-05-20 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
US20050026874A1 (en) * | 2002-07-29 | 2005-02-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease |
EP1753708B1 (en) * | 2004-01-20 | 2018-02-21 | Brigham Young University | Novel sirtuin activating compounds and methods for making the same |
US7691901B2 (en) * | 2004-04-14 | 2010-04-06 | Cardax Pharmaceuticals Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
US20060058269A1 (en) * | 2004-04-14 | 2006-03-16 | Lockwood Samuel F | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
US20060088905A1 (en) * | 2004-10-01 | 2006-04-27 | Lockwood Samuel F | Methods for the synthesis of zeazanthin |
JP2007238441A (ja) * | 2004-12-03 | 2007-09-20 | Fuji Chem Ind Co Ltd | アスタキサンチンを有効成分とする体脂肪減少用組成物 |
CA2592142A1 (en) * | 2004-12-22 | 2006-06-29 | Emory University | Therapeutic adjuncts to enhance the organ protective effects of postconditioning |
US20060270589A1 (en) * | 2005-02-22 | 2006-11-30 | Lockwood Samuel F | Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of visual disabilities |
KR101315904B1 (ko) * | 2005-02-24 | 2013-10-08 | 디퓨젼 파마슈티컬즈 엘엘씨 | 트랜스 카로티노이드, 이들의 합성, 제제화 및 용도 |
WO2006099015A2 (en) * | 2005-03-09 | 2006-09-21 | Cardax Pharmaceuticals, Inc. | Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders |
EA016258B1 (ru) | 2005-03-18 | 2012-03-30 | Микробиа, Инк. | Рекомбинантные грибы, продуцирующие каротиноиды, и способы их применения |
CA2611137A1 (en) * | 2005-03-23 | 2006-09-28 | Cardax Pharmaceuticals, Inc. | Water-dispersible carotenoids, including analogs and derivatives |
WO2006105214A2 (en) * | 2005-03-29 | 2006-10-05 | Cardax Pharmaceuticals, Inc. | Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof |
JP2006016407A (ja) * | 2005-06-15 | 2006-01-19 | Yamaha Motor Co Ltd | ホスホジエステラーゼ阻害剤 |
JP2006016408A (ja) * | 2005-06-23 | 2006-01-19 | Yamaha Motor Co Ltd | 血中中性脂肪抑制剤 |
JP2007153845A (ja) * | 2005-12-07 | 2007-06-21 | Yamaha Motor Co Ltd | 脂肪蓄積抑制剤 |
EP1957057A1 (en) * | 2005-12-07 | 2008-08-20 | Cardax Pharmaceuticals, Inc. | Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status |
US20070135521A1 (en) * | 2005-12-14 | 2007-06-14 | Yamaha Hatsudoki Kabushiki Kaisha | Agent for Preventing Metabolic Syndrome |
WO2007090095A2 (en) * | 2006-01-27 | 2007-08-09 | Cardax Pharmaceuticals, Inc. | Synthesis of carotenoid analogs or derivatives with improved antioxidant characteristics |
WO2007147163A2 (en) * | 2006-06-16 | 2007-12-21 | Cardax Pharmaceuticals, Inc. | Compositions comprising carotenoid analogs or derivatives and methods for synthesis |
CL2007002299A1 (es) * | 2006-08-08 | 2009-08-07 | Nestec Sa | Composición primaria estable que contiene licopeno enriquecido en isómeros z; proceso de preparación; composición oral que la comprende; composición cosmética que la comprende; y su uso para mejorar la salud de la piel y mejorar la calidad del cabello. |
US8691555B2 (en) | 2006-09-28 | 2014-04-08 | Dsm Ip Assests B.V. | Production of carotenoids in oleaginous yeast and fungi |
ITMI20061874A1 (it) * | 2006-09-29 | 2006-12-29 | Rosario Ammirante | Composizione per il trattamento degli stati patologici neurodegenerativi del sistema nervoso centrale ed in particolare nel morbo di parkinson |
WO2008118862A1 (en) * | 2007-03-23 | 2008-10-02 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs and derivatives for the prevention of platelet aggregation |
AU2008246305B2 (en) | 2007-04-13 | 2013-03-21 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease |
JP2011502125A (ja) * | 2007-10-31 | 2011-01-20 | ディフュージョン・ファーマシューティカルズ・エルエルシー | 小分子拡散を促進する新しい種類の治療法 |
US20090297492A1 (en) * | 2008-05-30 | 2009-12-03 | Yamaha Hatsudoki Kabushiki Kaisha | Method for Improving Cognitive Performance |
WO2010120686A2 (en) * | 2009-04-13 | 2010-10-21 | Parsons J Kellogg | Methods for the diagnosis and treatment of benign prostatic hyperplasia |
CN102458110A (zh) | 2009-06-22 | 2012-05-16 | 扩散药品有限公司 | 扩散促进化合物及其单独或与溶栓药一起的应用 |
EP2464350B1 (en) * | 2009-09-11 | 2016-08-24 | Nestec S.A. | Compositions and methods for enhancing cognitive and related functions in animals |
US8541645B2 (en) * | 2009-10-22 | 2013-09-24 | University Of Calcutta | Animal model for cigarette-smoke-induced atherosclerosis and related methods |
ES2654945T3 (es) | 2010-06-02 | 2018-02-15 | Diffusion Pharmaceuticals Llc | Formulaciones orales de carotenoides trans bipolares |
US20130129713A1 (en) * | 2010-08-04 | 2013-05-23 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Method of antigen loading for immunotherapy |
CN102389407A (zh) * | 2011-12-01 | 2012-03-28 | 滨州医学院 | 虾青素在制备治疗和预防肺纤维化的药品中的应用 |
WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
GB201120772D0 (en) * | 2011-12-02 | 2012-01-11 | Ip Science Ltd | Cocoa-based food products |
CN110051672A (zh) * | 2012-07-09 | 2019-07-26 | 诺格罗有限责任公司 | 使用膳食补充剂预防酒精反应 |
CN103073471B (zh) * | 2013-01-30 | 2014-11-05 | 江苏省农业科学院 | 一种叶黄素二琥珀酸酯的超声辅助合成方法 |
US9482675B1 (en) * | 2013-07-31 | 2016-11-01 | University Of Kentucky Research Foundation | Methods and systems for prognosis and diagnosis of brain damage |
JP6183746B2 (ja) * | 2013-11-13 | 2017-08-23 | 国立大学法人高知大学 | 遅延性アレルギー抑制剤 |
RU2693455C2 (ru) | 2014-05-20 | 2019-07-03 | Аста Фармасьютикалз Ко., Лтд. | Каротеноидное производное, его фармацевтически приемлемая соль и фармацевтическая композиция, содержащая его |
WO2016063278A1 (en) * | 2014-10-19 | 2016-04-28 | Shenkar College Of Engineering And Design | Astaxanthin based polymer and uses thereof |
MX2017014197A (es) | 2015-05-08 | 2018-08-15 | Spectral Platforms Inc | Complejos no covalentes basados en albumina y metodos de uso de los mismos. |
US20160367620A1 (en) | 2015-06-19 | 2016-12-22 | Harry B. Demopoulos | Glutathione |
US9572783B1 (en) * | 2015-10-08 | 2017-02-21 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
CN105646869B (zh) * | 2016-01-04 | 2018-01-16 | 中国海洋大学 | 一种水溶性虾青素衍生物及其制备方法 |
JP7032320B2 (ja) * | 2016-03-24 | 2022-03-08 | ディフュージョン・ファーマシューティカルズ・エルエルシー | 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用 |
CN106748946A (zh) * | 2017-02-14 | 2017-05-31 | 烟台固特丽生物科技股份有限公司 | 一种含水溶性虾青素作物营养液的制备方法 |
EP3602065A4 (en) | 2017-03-20 | 2020-12-23 | Spectral Platforms, Inc. | SPECTROSCOPIC METHODS OF DETECTION AND CHARACTERIZATION OF MICROORGANISMS |
EP3787607A4 (en) * | 2018-05-03 | 2022-03-09 | L.E.A.F Holdings Group LLC | CAROTENOID COMPOSITIONS AND THEIR USES |
JP2021176821A (ja) * | 2018-08-01 | 2021-11-11 | アスタファーマシューティカルズ株式会社 | 新規カロテノイド関連誘導体、その塩又はエステル類若しくはアミド類 |
CN109678771A (zh) * | 2018-12-28 | 2019-04-26 | 广州立达尔生物科技股份有限公司 | 一种叶黄素甘氨酸酯及其盐酸盐的制备方法 |
KR20220088706A (ko) * | 2019-09-27 | 2022-06-28 | 카닥스 아이엔씨 | 아스타잔틴 에스테르 및 이의 사용 방법 |
FR3105790B1 (fr) * | 2019-12-26 | 2022-01-14 | Biophytis | Composés chimiques ciblant l’œil et leur utilisation dans le traitement de maladies oculaires |
CN111257466B (zh) * | 2020-02-27 | 2022-04-01 | 南宁海关技术中心 | 一种红心鸭蛋中类胡萝卜素含量的测定方法 |
CN113788867B (zh) * | 2021-06-30 | 2023-12-26 | 东北林业大学 | 一种叶黄素水溶性衍生物及其制备工艺 |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH314001A (de) * | 1952-12-18 | 1956-05-31 | Hoffmann La Roche | Verfahren zur Herstellung von Vitamin-A-Estern |
CH420822A (de) * | 1960-10-17 | 1966-09-15 | Hoffmann La Roche | Wasserdispergierbare Carotinoidzubereitung |
US3354218A (en) * | 1963-05-10 | 1967-11-21 | Hoffmann La Roche | Process for preparing 4-(2, 6, 6-trimethyl-4-methoxy-1-cyclohexen-1-yl)-3-buten-2-one |
FR2076448A5 (US20050075337A1-20050407-C00035.png) | 1970-01-15 | 1971-10-15 | Rhone Poulenc Sa | |
US3853993A (en) * | 1973-05-01 | 1974-12-10 | Univ Virginia | Process for increasing oxygen diffusivity and method for treating atherosclerosis |
US3788468A (en) * | 1973-05-01 | 1974-01-29 | Univ Virginia | Process for increasing oxygen diffusivity |
US3989757A (en) | 1973-08-29 | 1976-11-02 | Hoffmann-La Roche Inc. | Isomerizing cis-carotenoids to all-trans-carotenoids |
CH609320A5 (US20050075337A1-20050407-C00035.png) * | 1974-06-20 | 1979-02-28 | Hoffmann La Roche | |
US3965261A (en) | 1975-04-29 | 1976-06-22 | University Of Virginia | Method for treating papillomas |
US3975519A (en) | 1975-06-09 | 1976-08-17 | University Of Virginia | Method for increasing the oxygen partial pressure in the bloodstream of mammals |
US4070460A (en) | 1975-11-10 | 1978-01-24 | University Of Virginia Patents Foundation | Method for treating cerebral edema |
US4009270A (en) | 1975-11-21 | 1977-02-22 | The University Of Virginia | Method for treating spinal cord injury |
CH623304A5 (US20050075337A1-20050407-C00035.png) * | 1975-11-30 | 1981-05-29 | Hoffmann La Roche | |
US4038144A (en) | 1976-04-19 | 1977-07-26 | The University Of Virginia | Method of increasing fermentation yields |
US4046880A (en) | 1976-04-20 | 1977-09-06 | The University Of Virginia | Method of treating hypertension |
JPS6053031B2 (ja) | 1978-03-31 | 1985-11-22 | 武田薬品工業株式会社 | スピロ化合物およびその製造方法 |
US4176179A (en) | 1978-04-17 | 1979-11-27 | The University Of Virginia Alumni Patents Foundation | Method for treating arthritis |
EP0005748B1 (de) * | 1978-06-02 | 1982-12-29 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Verfahren zur Herstellung von Cyclohexenderivaten sowie Zwischenprodukte in diesem Verfahren |
DE2965093D1 (en) * | 1978-06-02 | 1983-05-05 | Hoffmann La Roche | Derivatives of cyclohexene, process for their peparation, as well as their uses |
DE3048000A1 (de) | 1980-12-19 | 1982-07-15 | Basf Ag | Stabile injizierbare (beta)-carotin-solubilisate und verfahren zu ihrer herstellung |
EP0077439B1 (de) * | 1981-10-16 | 1986-09-24 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Verfahren zur Herstellung von Cyclohexenderivaten, sowie ein neues Ausgangsprodukt und neue Zwischenprodukte in diesem Verfahren |
ATE13666T1 (de) * | 1982-02-09 | 1985-06-15 | Hoffmann La Roche | Verfahren zur herstellung von cyclohexenderivaten. |
EP0101597B1 (de) * | 1982-08-20 | 1988-06-22 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Verfahren zur Herstellung von Astaxanthin und Zwischenprodukten in der Astaxanthin-Synthese |
US4491574A (en) | 1983-03-02 | 1985-01-01 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Reduction of high dose aspirin toxicity by dietary vitamin A |
EP0151989B1 (de) | 1984-01-28 | 1991-04-10 | Roshdy Dr. Ismail | Mittel zur Behandlung von Herzerkrankungen |
US5346488A (en) | 1985-04-08 | 1994-09-13 | The General Hospital Corporation | Laser-induced ablation of atherosclerotic plaque |
US4851339A (en) * | 1986-04-01 | 1989-07-25 | Hills Christopher B | Extraction of anti-mutagenic pigments from algae and vegetables |
DK171297B1 (da) * | 1987-03-27 | 1996-08-26 | Hoffmann La Roche | Fremgangsmåde til fremstilling af cyclohexenderivater som mellemprodukter til fremstilling af zeaxanthin samt cyclohexenderivater |
US5057494A (en) | 1988-08-03 | 1991-10-15 | Ethicon, Inc. | Method for preventing tissue damage after an ischemic episode |
DE59003205D1 (de) | 1989-07-25 | 1993-12-02 | Hoffmann La Roche | Verfahren zur Herstellung von Carotinoidpräparaten. |
US5278189A (en) | 1990-06-04 | 1994-01-11 | Rath Matthias W | Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A) |
CA2093008A1 (en) | 1990-10-01 | 1992-04-02 | Charles H. Hennekens | Beta-carotene and vitamin e therapy for inhibition of major vascular events |
US6132790A (en) | 1991-09-06 | 2000-10-17 | Betatene Limited | Carotenoid composition |
CA2125888C (en) | 1992-01-06 | 2002-08-27 | Harry B. Demopoulos | Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty |
US5221668A (en) | 1992-02-26 | 1993-06-22 | Abbott Laboratories | Nutritional product for trauma and surgery patients |
IL104736A0 (en) | 1992-03-27 | 1993-06-10 | Zeagen Inc | Method for producing beta-carotene using a fungal mated culture |
US5328845A (en) | 1992-03-27 | 1994-07-12 | Universal Foods Corporation | Fungal negative microorganism capable of producing high levels of beta-carotene |
DK0565989T3 (da) | 1992-04-14 | 1997-12-15 | Hoffmann La Roche | Præparater af fedtopløselige stoffer |
US5310764A (en) | 1992-05-08 | 1994-05-10 | Steven Baranowitz | Treatment of age related macular degeneration with beta-carotene |
US5612485A (en) | 1992-06-04 | 1997-03-18 | Betatene Ltd Of Cheltenham | High cis beta-carotene composition |
GB9219524D0 (en) | 1992-09-15 | 1992-10-28 | Smithkline Beecham Plc | Novel composition |
US5310554A (en) | 1992-10-27 | 1994-05-10 | Natural Carotene Corporation | High purity beta-carotene |
DE19609538A1 (de) | 1996-03-11 | 1997-09-18 | Basf Ag | Feinverteilte Carotinoid- und Retinoidsuspensionen und Verfahren zu ihrer Herstellung |
WO1994021231A1 (en) | 1993-03-22 | 1994-09-29 | Betatene Limited | Therapeutic agent for the treatment of melanomas |
US5773026A (en) | 1993-03-22 | 1998-06-30 | Betatene Limited | Aqueous formulations of water-insoluble therapeutic agent comprising carotenoids and/or tocopherols |
DE69424719T2 (de) * | 1993-06-24 | 2000-11-02 | Hoffmann La Roche | Pigmentierung mit Carotinoiden |
US6218436B1 (en) | 1993-06-28 | 2001-04-17 | The Howard Foundation | Pharmaceutically active carotenoids |
DE4322277A1 (de) | 1993-07-05 | 1995-01-12 | Basf Ag | Verbessertes Verfahren zur Herstellung von Astaxanthin, neue Zwischenprodukte hierfür sowie ein Verfahren zu deren Herstellung |
FR2707184B1 (fr) | 1993-07-08 | 1995-08-11 | Rhone Poulenc Nutrition Animal | Procédé de préparation de sphérules contenant un principe actif alimentaire ou pharmaceutique. |
US5607839A (en) | 1993-07-22 | 1997-03-04 | Nippon Oil Company, Ltd. | Bacteria belonging to new genus process for production of carotenoids using same |
JP3249867B2 (ja) * | 1993-10-21 | 2002-01-21 | 株式会社クラレ | アスタキサンチンの製造方法 |
CH685189A5 (de) * | 1993-11-19 | 1995-04-28 | Marigen Sa | Ultramikroemulsionen aus spontan dispergierbaren Konzentraten mit antitumoral wirksamen Xanthophyll-Estern. |
US6428816B1 (en) | 1994-04-08 | 2002-08-06 | Cognis Australia Pty., Ltd. | Carotenoid agent for inhibiting the conversion of epithelial cells to tumors |
SE9401738D0 (sv) | 1994-05-19 | 1994-05-19 | Ewos Ab | Bioactive feed |
JPH0873312A (ja) * | 1994-09-02 | 1996-03-19 | Noevir Co Ltd | 皮膚外用剤 |
SE503336C2 (sv) | 1994-09-19 | 1996-05-28 | Asta Carotene Ab | Medel och sätt för att öka produktionen av/hos fjäderfän |
US5527533A (en) | 1994-10-27 | 1996-06-18 | Board Of Trustees Of The University Of Illinois | Method of retarding and ameliorating central nervous system and eye damage |
DE69511515T2 (de) | 1994-12-21 | 2000-01-20 | Hoffmann La Roche | Carotenoide Ketone und Ester |
US5643943A (en) | 1994-12-23 | 1997-07-01 | Alcon Laboratories, Inc. | Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis |
US5589468A (en) | 1995-01-13 | 1996-12-31 | Clintec Nutrition Co. | Method for providing nutrition to elderly patients |
JPH10513444A (ja) | 1995-02-03 | 1998-12-22 | ビーエーエスエフ アクチェンゲゼルシャフト | 皮膚疾患の治療のための医薬品の製造のためのカロチノイドの使用 |
US5532009A (en) * | 1995-06-07 | 1996-07-02 | The Procter & Gamble Company | Fat substitutes containing water soluble beta-carotene |
JPH08337592A (ja) * | 1995-06-13 | 1996-12-24 | Kaiyo Bio Technol Kenkyusho:Kk | 新規カロテノイド |
JPH0984591A (ja) * | 1995-09-26 | 1997-03-31 | Kaiyo Bio Technol Kenkyusho:Kk | カロテノイド硫酸エステルおよびその製造方法 |
US6060511A (en) | 1995-10-05 | 2000-05-09 | Gainer; John L. | Trans-sodium crocetinate, methods of making and methods of use thereof |
US5965750A (en) | 1995-10-17 | 1999-10-12 | Showa Denko K.K. | High- purity tocopherol phosphates, process for the preparation thereof, methods for analysis thereof, and cosmetics |
JPH09124470A (ja) | 1995-10-26 | 1997-05-13 | Suntory Ltd | 抗ストレス組成物 |
US5854015A (en) | 1995-10-31 | 1998-12-29 | Applied Food Biotechnology, Inc. | Method of making pure 3R-3'R stereoisomer of zeaxanthin for human ingestion |
US5827539A (en) | 1995-12-28 | 1998-10-27 | Amway Corporation | Dry carotenoid-oil powder and process for making same |
US5837224A (en) | 1996-01-19 | 1998-11-17 | The Regents Of The University Of Michigan | Method of inhibiting photoaging of skin |
US6232060B1 (en) | 1996-01-19 | 2001-05-15 | Galileo Laboratories, Inc. | Assay system for anti-stress agents |
JPH09202730A (ja) * | 1996-01-24 | 1997-08-05 | Nippon Mektron Ltd | 発ガン抑制作用剤 |
US5801159A (en) | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
DE19609476A1 (de) | 1996-03-11 | 1997-09-18 | Basf Ag | Stabile zur parenteralen Verabreichung geeignete Carotinoid-Emulsionen |
DE19609477A1 (de) | 1996-03-11 | 1997-09-18 | Basf Ag | Stabile wäßrige Solubilisate von Carotinoiden und Vitamine |
SE506191C2 (sv) | 1996-03-27 | 1997-11-17 | Astacarotene Ab | Medel och sätt för att öka produktionen av/hos däggdjur |
DK0807431T3 (da) | 1996-05-14 | 2004-07-26 | Dsm Ip Assets Bv | Fremgangsmåde til fremstilling af carotenoidpræparater |
DE19637517A1 (de) | 1996-09-13 | 1998-03-19 | Basf Ag | Herstellung von pulverförmigen, kaltwasserdispergierbaren Carotinoid-Zubereitungen und die Verwendung der neuen Carotinoid-Zubereitungen |
DE19649062A1 (de) | 1996-11-27 | 1998-05-28 | Basf Ag | Flüssige, mit Öl mischbare Carotinoid-Zubereitungen |
US20020032176A1 (en) * | 1996-12-25 | 2002-03-14 | Takashi Maoka | Carcinogenesis inhibitors |
ATE290375T1 (de) | 1997-04-02 | 2005-03-15 | Brigham & Womens Hospital | Verwendung eines mittels zur verminderung des risikos kardiovaskulärer erkrankungen |
US5858700A (en) | 1997-04-03 | 1999-01-12 | Kemin Foods, Lc | Process for the isolation and purification of lycopene crystals |
AU752468B2 (en) * | 1997-04-04 | 2002-09-19 | Phyllis E. Bowen | Lutein esters having high bioavailability |
US5811446A (en) | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
US5876782A (en) | 1997-05-14 | 1999-03-02 | Kemin Industries, Inc. | Method for the conversion of xanthophylls in plant material |
JPH10327865A (ja) * | 1997-05-29 | 1998-12-15 | Kirin Brewery Co Ltd | カロテノイド配糖体およびその製造法 |
SE512531C2 (sv) | 1997-09-04 | 2000-03-27 | Astacarotene Ab | Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur |
US6008417A (en) | 1997-10-20 | 1999-12-28 | Roche Vitamins Inc. | Process for making metabolites of lycopene |
US5959138A (en) | 1997-11-25 | 1999-09-28 | Industrial Organica S.A. De C.V. | Short chain diesters and process for making the same |
SE511237C2 (sv) | 1997-12-16 | 1999-08-30 | Astacarotene Ab | Användning av åtminstone en typ av xantofyller för framställning av ett humant eller verinärmedicinskt läkemedel för profylaktisk behandling av mastit hos däggdjursmammor |
DE19802134A1 (de) * | 1998-01-21 | 1999-07-22 | Basf Ag | Verwendung von Carotinoid-Aggregaten als Färbemittel |
US6020003A (en) | 1998-02-23 | 2000-02-01 | Basf Corporation | Method of making spray-dried powders with high edible-oil loadings based on non-hydrolyzed gelatin |
US6051587A (en) | 1998-04-16 | 2000-04-18 | Medicure, Inc. | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein |
US6331537B1 (en) | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
US6043259A (en) | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
NL1010351C2 (nl) * | 1998-10-19 | 2001-01-08 | Werklust & Beheer B V | Esters van caroteno´den voor gebruik in de preventie en behandeling van oogaandoeningen. |
US6075058A (en) | 1998-12-12 | 2000-06-13 | Tufts University | Compositions for increased bioavailability of carotenoids |
US6399105B1 (en) | 1999-01-20 | 2002-06-04 | Peter Donald Collin | Sea cucumber carotenoid lipid fraction products and methods of use |
US6426362B1 (en) | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
JP4491090B2 (ja) * | 1999-10-08 | 2010-06-30 | ヒガシマル醤油株式会社 | アポトーシス誘導剤 |
AU2257401A (en) | 1999-12-08 | 2001-06-18 | California Institute Of Technology | Directed evolution of biosynthetic and biodegration pathways |
US6344214B1 (en) | 1999-12-13 | 2002-02-05 | Cyanotech Corporation | Method for retarding and ameliorating fever blisters and canker sores |
US6258855B1 (en) | 2000-02-08 | 2001-07-10 | Cyanotech Corporation | Method of retarding and ameliorating carpal tunnel syndrome |
AU5137901A (en) | 2000-04-06 | 2001-10-23 | Coastside Res | Method to inhibit lipoxygenase and cancer cell proliferation |
US20030104090A1 (en) | 2000-05-05 | 2003-06-05 | Levy Pedro E. | Supplements containing annatto extracts and carotenoids and methods for using the same |
US6579544B1 (en) | 2000-05-31 | 2003-06-17 | Nutriex, L.L.C. | Method for supplementing the diet |
US20020110604A1 (en) | 2000-08-11 | 2002-08-15 | Ashni Naturaceuticals, Inc. | Composition exhibiting synergistic antioxidant activity |
WO2002047493A2 (en) | 2000-12-16 | 2002-06-20 | Aventis Pharma Deutschland Gmbh | Health promoting compositions |
MXPA03007561A (es) | 2001-02-23 | 2004-10-15 | Barlovento Internat | Esteres carotenoides novedosos. |
US6984523B2 (en) | 2001-08-02 | 2006-01-10 | E.I. Du Pont De Nemours And Company | Carotenoid ketolase gene |
GB0119052D0 (en) | 2001-08-03 | 2001-09-26 | Mars Uk Ltd | Foodstuff |
EP1474388B2 (en) * | 2002-02-06 | 2013-03-06 | DSM IP Assets B.V. | Astaxanthin esters |
US7514107B2 (en) | 2002-03-21 | 2009-04-07 | Mars, Incorporated | Treatment of diseases involving defective gap junctional communication |
CN100374417C (zh) * | 2002-04-30 | 2008-03-12 | 三得利株式会社 | 虾青素中链脂肪酸酯、其制造方法、以及含有其的组合物 |
CA2495167C (en) * | 2002-07-29 | 2018-08-21 | Hawaii Biotech, Inc. | Structural carotenoid analogs for the inhibition and amelioration of disease |
US7723327B2 (en) | 2002-07-29 | 2010-05-25 | Cardax Pharmaceuticals, Inc. | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease |
US20050049248A1 (en) | 2002-07-29 | 2005-03-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels |
US20050026874A1 (en) | 2002-07-29 | 2005-02-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease |
US7320997B2 (en) | 2002-07-29 | 2008-01-22 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease |
US20050004235A1 (en) | 2002-07-29 | 2005-01-06 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease |
US7763649B2 (en) | 2002-07-29 | 2010-07-27 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for controlling connexin 43 expression |
US7375133B2 (en) | 2002-07-29 | 2008-05-20 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
US20050059635A1 (en) | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels |
US20050148517A1 (en) * | 2002-07-29 | 2005-07-07 | Lockwood Samuel F. | Carotenoid ether analogs or derivatives for controlling connexin 43 expression |
US20050059659A1 (en) | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for controlling C-reactive protein levels |
US20050143475A1 (en) | 2002-07-29 | 2005-06-30 | Lockwood Samuel F. | Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury |
US7345091B2 (en) | 2002-07-29 | 2008-03-18 | Cardax Pharmaceuticals, Inc. | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
US20050009788A1 (en) | 2002-07-29 | 2005-01-13 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling connexin 43 expression |
US7521584B2 (en) | 2002-07-29 | 2009-04-21 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of disease |
US20060058269A1 (en) * | 2004-04-14 | 2006-03-16 | Lockwood Samuel F | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
US7691901B2 (en) * | 2004-04-14 | 2010-04-06 | Cardax Pharmaceuticals Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
US20060088905A1 (en) * | 2004-10-01 | 2006-04-27 | Lockwood Samuel F | Methods for the synthesis of zeazanthin |
-
2003
- 2003-07-29 CA CA2495167A patent/CA2495167C/en not_active Expired - Fee Related
- 2003-07-29 KR KR1020057001714A patent/KR20050069975A/ko not_active Application Discontinuation
- 2003-07-29 BR BRPI0313155A patent/BRPI0313155B8/pt not_active IP Right Cessation
- 2003-07-29 US US10/629,538 patent/US7145025B2/en not_active Expired - Lifetime
- 2003-07-29 CN CN2010101657116A patent/CN101845009B/zh not_active Expired - Fee Related
- 2003-07-29 EP EP10185924.7A patent/EP2392562B1/en not_active Expired - Lifetime
- 2003-07-29 WO PCT/US2003/023706 patent/WO2004011423A2/en active Search and Examination
- 2003-07-29 JP JP2005505633A patent/JP4601549B2/ja not_active Expired - Fee Related
- 2003-07-29 EP EP03772051.3A patent/EP1532108B1/en not_active Expired - Lifetime
- 2003-07-29 CN CN03823260XA patent/CN1708480B/zh not_active Expired - Fee Related
- 2003-07-29 MX MXPA05001202A patent/MXPA05001202A/es not_active Application Discontinuation
- 2003-07-29 AU AU2003256982A patent/AU2003256982A1/en not_active Abandoned
-
2004
- 2004-03-04 US US10/793,696 patent/US20050065097A1/en not_active Abandoned
- 2004-03-04 US US10/793,702 patent/US20050075337A1/en not_active Abandoned
- 2004-03-04 US US10/793,703 patent/US7317008B2/en not_active Expired - Lifetime
-
2005
- 2005-02-03 NO NO20050619A patent/NO20050619L/no not_active Application Discontinuation
-
2006
- 2006-02-17 US US11/357,897 patent/US7592449B2/en not_active Expired - Lifetime
- 2006-04-20 HK HK06104731.0A patent/HK1084380A1/xx not_active IP Right Cessation
-
2010
- 2010-07-29 JP JP2010170929A patent/JP5187700B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-28 HK HK11103076.8A patent/HK1148997A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2004011423A2 (en) | 2004-02-05 |
BRPI0313155B1 (pt) | 2018-11-06 |
JP2010248243A (ja) | 2010-11-04 |
HK1148997A1 (en) | 2011-09-23 |
EP2392562B1 (en) | 2018-03-07 |
EP2392562A1 (en) | 2011-12-07 |
EP1532108A2 (en) | 2005-05-25 |
US20050075337A1 (en) | 2005-04-07 |
US20050037995A1 (en) | 2005-02-17 |
AU2003256982A1 (en) | 2004-02-16 |
CN1708480B (zh) | 2010-12-15 |
HK1084380A1 (en) | 2006-07-28 |
US7317008B2 (en) | 2008-01-08 |
US20050065097A1 (en) | 2005-03-24 |
CN101845009B (zh) | 2012-10-03 |
JP2006517197A (ja) | 2006-07-20 |
CN101845009A (zh) | 2010-09-29 |
US20040162329A1 (en) | 2004-08-19 |
KR20050069975A (ko) | 2005-07-05 |
US20060229446A1 (en) | 2006-10-12 |
EP1532108B1 (en) | 2016-06-29 |
CA2495167C (en) | 2018-08-21 |
US7592449B2 (en) | 2009-09-22 |
JP5187700B2 (ja) | 2013-04-24 |
CN1708480A (zh) | 2005-12-14 |
MXPA05001202A (es) | 2005-11-23 |
US7145025B2 (en) | 2006-12-05 |
BR0313155A (pt) | 2005-07-12 |
JP4601549B2 (ja) | 2010-12-22 |
BRPI0313155B8 (pt) | 2021-05-25 |
WO2004011423A3 (en) | 2004-05-06 |
CA2495167A1 (en) | 2004-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20050619L (no) | Strukturelle korotenoid analoger for inhibisjon og lindring av sykdom | |
Rady et al. | Anticancer properties of graviola (Annona muricata): a comprehensive mechanistic review | |
JP5466403B2 (ja) | 皮膚の炎症状態の治療用の植物水組成物 | |
Athiroh et al. | Antioxidative and blood pressure-lowering effects of Scurrula atropurpurea on deoxycorticosterone acetate–salt hypertensive rats | |
JP2015523366A (ja) | スルホラファンまたはスルホラファン前駆体およびキノコ抽出物または粉末を含む組成物 | |
HUP0104718A2 (hu) | Mikronizált eplerenon kompozíciók és eljárás az előállításukra | |
KR20120047240A (ko) | 주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물 | |
HK1083196A1 (en) | Topical compositions having a natural ingredient and method of use | |
KR20100117074A (ko) | 캡시쿰을 포함하는, 피부 질환 치료용 조성물 | |
JPH0517365A (ja) | テストステロン 5α−レダクターゼ阻害剤 | |
US20120316144A1 (en) | Antifungal agent | |
TW201642849A (zh) | 包括芝麻素之組成物、其製造方法及用於皮膚抗老化及皮膚美白應用之用途 | |
Hoshyar et al. | The cytotoxic activity of Ziziphus Jujube on cervical cancer cells: In Vitro study | |
EP1791423B1 (en) | Compositions and methods for the management of hyperproliferative dermatological conditions | |
KR20070074690A (ko) | 향유 추출물을 함유하는 테스토스테론 5알파-리덕타아제저해제 | |
CN113101289A (zh) | 烟酰胺在制备治疗手足皮肤反应制剂中的应用 | |
EP2004235B1 (en) | Composition for cosmetic or pharmaceutical-dermatological use | |
Ali | Use of acacia gum in the treatment of skin lesions of two children with Kwashiorkor | |
CA2489705A1 (en) | Use of amide derivative of ge 2270 factor a3 for the treatment of acne | |
CN107072979A (zh) | 类黄酮化合物在制备伤口愈合组合物的用途 | |
US11896611B1 (en) | Phytochemical/ nutraceutical composition for multimodal prophylaxis against and treatment of viral and bacterial infection and inflammation | |
KR20170140791A (ko) | 부종의 치료, 예방 또는 개선용 조성물 | |
US11065229B2 (en) | Method for reducing itching in atopic dermatitis | |
Mohammed | Hypolipidemic and Anti-Oxidant Effects of Curcumin in Dexamethasone-Induced Dyslipidemia in Rats | |
Patel et al. | Study of the antinociceptive effect of neem leaf extract and its interaction with morphine in mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |